Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 235 / Friday, December 10, 2021 / Rules and Regulations effective September 15, 2021, is amended as follows:
Paragraph 6005 Class E Airspace Areas Extending Upward From 700 Feet or More Above the Surface of the Earth.

ASO KY E5 Ashland, KY Amended Ashland Regional Airport, KY
Lat. 383316 N, long. 824416 W
That airspace extending upward from 700
feet above the surface within a 6.5-mile radius of the Ashland Regional Airport, and extending 2 miles either side of the 098
bearing from the airport extending from the 6.5-mile radius to 10.4 miles east of the airport, and extending 2 miles either side of the 278 bearing from the airport extending from the 6.5-mile radius to 10.5 miles west of the airport.
Issued in Fort Worth, Texas, on December 7, 2021.
Steven T. Phillips, Acting Manager, Operations Support Group, ATO Central Service Center.
FR Doc. 202126785 Filed 12921; 8:45 am BILLING CODE 491013P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration 21 CFR Part 876
Docket No. FDA2021N0585

Medical Devices; GastroenterologyUrology Devices; Classification of the Ingested, Transient, Space Occupying Device for Weight Management and/or Weight Loss Food and Drug Administration, Department of Health and Human Services HHS.
ACTION: Final amendment; final order.
AGENCY:

The Food and Drug Administration FDA or we is classifying the ingested, transient, space occupying device for weight management and/or weight loss into class II special controls. The special controls that apply to the device type are identified in this order and will be part of the codified language for the ingested, transient, space occupying device for weight management and/or weight losss classification. We are taking this action because we have determined that classifying the device into class II special controls will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients access to beneficial innovative devices.

jspears on DSK121TN23PROD with RULES1

SUMMARY:

VerDate Sep<11>2014

15:55 Dec 09, 2021

Jkt 256001

This order is effective December 10, 2021. The classification was applicable on April 12, 2019.
FOR FURTHER INFORMATION CONTACT:
April Marrone, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G218, Silver Spring, MD 209930002, 2404026510, April.Marrone@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
DATES:

I. Background Upon request, FDA has classified the ingested, transient, space occupying device for weight management and/or weight loss as class II special controls, which we have determined will provide a reasonable assurance of safety and effectiveness. In addition, we believe this action will enhance patients access to beneficial innovation by placing the device into a lower device class than the automatic class III assignment.
The automatic assignment of class III
occurs by operation of law and without any action by FDA, regardless of the level of risk posed by the new device.
Any device that was not in commercial distribution before May 28, 1976, is automatically classified as, and remains within, class III and requires premarket approval unless and until FDA takes an action to classify or reclassify the device see 21 U.S.C. 360cf1. We refer to these devices as postamendments devices because they were not in commercial distribution prior to the date of enactment of the Medical Device Amendments of 1976, which amended the Federal Food, Drug, and Cosmetic Act FD&C Act.
FDA may take a variety of actions in appropriate circumstances to classify or reclassify a device into class I or II. We may issue an order finding a new device to be substantially equivalent under section 513i of the FD&C Act 21
U.S.C. 360ci to a predicate device that does not require premarket approval.
We determine whether a new device is substantially equivalent to a predicate device by means of the procedures for premarket notification under section 510k of the FD&C Act 21 U.S.C.
360k and part 807 21 CFR part 807.
FDA may also classify a device through De Novo classification, a common name for the process authorized under section 513f2 of the FD&C Act. Section 207 of the Food and Drug Administration Modernization Act of 1997 established the first procedure for De Novo classification Pub. L. 105
115. Section 607 of the Food and Drug Administration Safety and Innovation Act modified the De Novo application process by adding a second procedure
PO 00000

Frm 00023

Fmt 4700

Sfmt 4700

70371

Pub. L. 112144. A device sponsor may utilize either procedure for De Novo classification.
Under the first procedure, the person submits a 510k for a device that has not previously been classified. After receiving an order from FDA classifying the device into class III under section 513f1 of the FD&C Act, the person then requests a classification under section 513f2.
Under the second procedure, rather than first submitting a 510k and then a request for classification, if the person determines that there is no legally marketed device upon which to base a determination of substantial equivalence, that person requests a classification under section 513f2 of the FD&C Act.
Under either procedure for De Novo classification, FDA is required to classify the device by written order within 120 days. The classification will be according to the criteria under section 513a1 of the FD&C Act.
Although the device was automatically placed within class III, the De Novo classification is considered to be the initial classification of the device.
When FDA classifies a device into class I or II via the De Novo process, the device can serve as a predicate for future devices of that type, including for 510ks see 21 U.S.C. 360cf2Bi.
As a result, other device sponsors do not have to submit a De Novo request or premarket approval application to market a substantially equivalent device see 21 U.S.C. 360ci, defining substantial equivalence. Instead, sponsors can use the less-burdensome 510k process, when necessary, to market their device.
II. De Novo Classification On November 15, 2018, Gelesis, Inc.
submitted a request for De Novo classification of the ingested, transient, space occupying device for weight management and/or weight loss. FDA
reviewed the request in order to classify the device under the criteria for classification set forth in section 513a1 of the FD&C Act.
We classify devices into class II if general controls by themselves are insufficient to provide reasonable assurance of safety and effectiveness, but there is sufficient information to establish special controls that, in combination with the general controls, provide reasonable assurance of the safety and effectiveness of the device for its intended use see 21 U.S.C.
360ca1B. After review of the information submitted in the request, we determined that the device can be classified into class II with the
E:FRFM10DER1.SGM

10DER1